KYMERA THERAPEUTICS, INC. Impairment Charge on Reclassified Assets
KYMERA THERAPEUTICS, INC. (KYMR) reported Impairment Charge on Reclassified Assets of $8.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentChargeOnReclassifiedAssets · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. impairment charge on reclassified assets for the quarter ending 2026-06-30 was $0.00.
- KYMERA THERAPEUTICS, INC. impairment charge on reclassified assets for the quarter ending 2026-03-31 was $8.80M, a 79.59% increase year-over-year.
- KYMERA THERAPEUTICS, INC. impairment charge on reclassified assets for the quarter ending 2025-12-31 was $0.00.
- KYMERA THERAPEUTICS, INC. impairment charge on reclassified assets for the quarter ending 2025-03-31 was $4.90M, a 0.00% change year-over-year.
- KYMERA THERAPEUTICS, INC. impairment charge on reclassified assets for fiscal 2025 was $3.90M, a 20.41% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. impairment charge on reclassified assets for fiscal 2024 was $4.90M.
| Period end | Impairment Charge on Reclassified Assets 3 month | Impairment Charge on Reclassified Assets 6 month | Impairment Charge on Reclassified Assets 9 month | Impairment Charge on Reclassified Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.80M 10-Q · filed 2026-08-05 | $8.80M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2026-03-31 | $8.80M 10-Q · filed 2026-04-30 | $8.80M derived: sum of 2 quarters · filed 2026-04-30 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.90M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $3.90M 10-Q · filed 2025-11-04 | |||
| 2025-03-31 | $4.90M 10-Q · filed 2025-08-11 | $4.90M derived: sum of 2 quarters · filed 2026-02-26 | $4.90M derived: sum of 3 quarters · filed 2026-02-26 | $4.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $4.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $4.90M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $4.90M 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $4.90M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |